Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E14.33 EPS (ttm)3.75 Insider Own0.04% Shs Outstand2.79B Perf Week-0.94%
Market Cap150.07B Forward P/E14.29 EPS next Y3.76 Insider Trans-8.05% Shs Float2.79B Perf Month0.47%
Income10.78B PEG2.86 EPS next Q0.90 Inst Own75.50% Short Float1.00% Perf Quarter-1.40%
Sales39.77B P/S3.77 EPS this Y176.90% Inst Trans-0.56% Short Ratio2.17 Perf Half Y-10.34%
Book/sh16.20 P/B3.32 EPS next Y5.53% ROA10.50% Target Price62.53 Perf Year-6.55%
Cash/sh4.33 P/C12.41 EPS next 5Y5.00% ROE22.90% 52W Range45.30 - 62.10 Perf YTD-3.09%
Dividend1.80 P/FCF243.22 EPS past 5Y-6.30% ROI0.50% 52W High-13.49% Beta0.64
Dividend %3.35% Quick Ratio1.30 Sales past 5Y9.00% Gross Margin63.70% 52W Low18.59% ATR0.92
Employees70000 Current Ratio1.60 Sales Q/Q-4.60% Oper. Margin16.10% RSI (14)54.68 Volatility1.09% 1.62%
OptionableYes Debt/Eq0.58 EPS Q/Q106.50% Profit Margin27.10% Rel Volume0.47 Prev Close53.48
ShortableYes LT Debt/Eq0.53 EarningsOct 27 BMO Payout47.10% Avg Volume12.83M Price53.72
Recom2.40 SMA20-1.07% SMA502.74% SMA200-3.84% Volume6,069,260 Change0.45%
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Nov-26-15 01:58PM  CheckMate -025 Study Supports Opdivos Approval
01:58PM  FDA Approves Opdivo for Additional Indications
12:04AM  Keytruda: Hope for Mercks Immuno-Oncology Franchise
12:04AM  Remicade: A Falling Drug in Mercks Immunology Franchise
Nov-25-15 04:25PM  Bristol-Myers' Opdivo Gets FDA Nod for Another Indication
06:52AM  Merck & Co., Inc. (MRK): Insiders Are Buying, Should You? at Insider Monkey
Nov-24-15 01:25PM  Will Merck (MRK) Stock Be Helped by Dividend Hike? at TheStreet
12:35PM  Merck Announces Increased Quarterly Dividend Business Wire
10:47AM  Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016 at 24/7 Wall St.
09:15AM  After Pfizer-Allergan Deal, Large Inversions May Be Hard to Find
07:41AM  This Metric Implies That It Might Be Time to Buy Big Pharma Stocks at Motley Fool
Nov-23-15 02:34PM  JAVELIN Series: Clinical Studies of Avelumab
02:34PM  Avelumab Receives Breakthrough Therapy Designation
10:01AM  Can Merck & Co. Take Down Gilead Sciences? at Motley Fool
09:44AM  Pfizer-Allergan Merger May Be Dwarfed By The Merck-Express Scripts Divide at Forbes
Nov-22-15 06:54PM  Pfizer set to buy Allergan for more than $150 bln-sources Reuters
09:12AM  Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting Back Against Cancer at Motley Fool
Nov-21-15 04:30PM  Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress Business Wire
09:04AM  Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C at Motley Fool
Nov-20-15 05:25PM  [$$] Celldex's Rindopepimut Cuts Death Risk From Brain Cancer, Study Shows at The Wall Street Journal
02:14PM  Gilead Sciences: Hepatitis-C Prescriptions Increase at
10:43AM  Studies Supporting Opdivos sBLA for Renal Cell Carcinoma
10:42AM  Opdivos sBLA Accepted by FDA for Priority Review
09:56AM  Germany's Merck aims to more than double Africa sales by 2020 at Financial Times
08:34AM  Health care is the best pick for 2016, despite Thursday's drop: Strategist
07:40AM  Merck & Co.'s Cholesterol-Buster Program Isn't (Yet) an Exercise in Futility at Motley Fool
07:05AM  Samsung's Challenger to Pfizer Drug Wins European Backing at Bloomberg
Nov-19-15 02:07PM  Vertex Rises on Two EU Approvals for Drug, Leads XLVs Large-Caps
10:10AM  Stock Market News for November 19, 2015
06:30AM  Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial PR Newswire
Nov-18-15 01:05PM  Global Drug Spending Will Reach $1.4 Trillion by 2020 at Fortune
12:10PM  Gilead Seen Staying Top Dog In HCV, But Merck Rising at Investor's Business Daily
10:18AM  5 Things Merck & Co., Inc. Wants You to Know at Motley Fool
Nov-17-15 03:52PM  Why Novavax Inc Is Moving Higher Today at Motley Fool
03:50PM  It's Income Investing Week at at
01:18PM  AbbVie: An Attractive Setup? at
10:59AM  Here's Why Advaxis' Stock Gained 11% in October at Motley Fool
09:34AM  Aura Series: Studies Supporting Approval of Targisso
08:00AM  New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses Business Wire
Nov-16-15 05:27PM  AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
10:35AM  Merck Prepares to Break Into HCV Market With Recent Study Results at 24/7 Wall St.
09:19AM  3 High-Yield Dividend Stocks You Don't Have to Babysit at Motley Fool
08:30AM  Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting® Business Wire
06:15AM  Lets Hope the Fed Doesn't Make a Second Mistake!
Nov-15-15 07:40AM  AstraZeneca urges antibiotics investment shake-up at Financial Times
Nov-14-15 08:12PM  1 Stock to Settle the Dividend vs. Buyback Debate at Forbes
07:00PM  Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Business Wire
07:00PM  Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy Business Wire
Nov-13-15 02:16PM  Merck continuing study of cholesterol drug in new class
01:04PM  MERCK & CO., INC. Financials
10:35AM  Immune Design Posts Narrower-Than-Expected Loss for Q3
08:34AM  Panel recommends Merck & Co continue cholesterol drug study Reuters
08:12AM  Panel recommends Merck continue cholesterol drug study Reuters
08:00AM  Merck Provides Update on REVEAL Outcomes Study Business Wire
07:27AM  Body's Microorganisms Could Keep Humans More Healthy at Forbes
Nov-12-15 05:00PM  Merck Animal Health to Acquire Harrisvaccines Business Wire
03:14PM  The high-flying health-care sector is now slowing dramatically at MarketWatch
01:23PM  Ex-BNY Mellon employee sentenced to 6 months in U.S. prison Reuters
01:03PM  U.S. appeals court invalidates four Merck Cubicin patents Reuters
12:58PM  [$$] Merck Loses Appeal in Cubicin Patent Case at The Wall Street Journal
12:00PM  Sigma-Aldrich's Buyout by Merck KGaA Gets Final EC Approval
11:49AM  Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation Business Wire
11:35AM  [$$] Germany's Merck: Tooling Up for Biotech Gold Rush at The Wall Street Journal
10:37AM  Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser?
10:07AM  Gardasil Is Driving Mercks Vaccine Business
10:01AM  Gilead Sciences: What's Next for Hepatitis C? at
08:07AM  Januvia and Janumet: Mercks Blockbuster Diabetes Products
07:37AM  [$$] Germany's Merck Lifts Outlook as Profit Jumps at The Wall Street Journal
06:50AM  Merck KGaA ups earnings outlook on strong biotech labs demand
06:30AM  Lexington firms new sepsis test places it among life sciences giants at
05:33AM  Germany, U.S. in hot pursuit of "messenger" drug molecules
03:50AM  Merck KGaA Raises Forecast as Profit Tops Estimates
01:15AM  Merck KGaA Raises Forecast as Quarterly Profit Tops Estimate at Bloomberg
Nov-11-15 04:28PM  The 4 Stocks That Held Down the Dow Jones Industrial Average at 24/7 Wall St.
10:58AM  Changes in Merck & Co.s Reported Business Segments in 2015
10:58AM  Merck & Co. Is Growing despite Its Revenue Falling in 3Q15
09:07AM  A Trio of Catalysts Lift Merck Higher in October at Motley Fool
08:15AM  Short Sellers Continue to Decrease Bets in Major Pharma at 24/7 Wall St.
06:00AM  'Mad Money' Lightning Round: Northrop Grumman, Lockheed Martin Both Terrific at TheStreet
Nov-10-15 07:00PM  Lightning Round: It's insane how much it went down at CNBC
05:35PM  Colorado's MiRagen attracts $41 million in VC backing for drugs at
04:25PM  What's in Store for Immune (IMDZ) this Earnings Season?
Nov-09-15 01:29PM  3 Buffett-Owned Stocks You Should Buy Today at TheStreet
04:30AM  What Does One Quarter or Half Percent Really Mean? Nothing!
Nov-07-15 01:20AM  [$$] Ackman Has Valeant's Ear at
Nov-06-15 10:29PM  [$$] Lilly, Merck and Valeant Receive Inquiries About Drug Pricing at The Wall Street Journal
03:49PM  [$$] Lilly, Merck Get Inquiries Over Drug Pricing at The Wall Street Journal
03:49PM  Why Incyte Corporation Shares Are Crashing Today at Motley Fool
03:10PM  FDA panel backs Merck & Co drug to reverse muscle relaxant effect Reuters
03:09PM  U.S. agencies investigate Merck, Lilly drug pricing
02:13PM  Merck Statement on FDA Advisory Committee Meeting for BRIDION® (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium Business Wire
02:03PM  FDA panel votes unanimously in favor of Merck & Co's Sugammadex Reuters
12:19PM  U.S. federal agencies investigate Merck, Lilly drug pricing Reuters
12:10PM  Merck (MRK) Stock Slides on Justice Department Inquiry at TheStreet
11:56AM  Merck & Co under Pennsylvania Attorney's Office probe over pricing Reuters
11:11AM  Merck's stock falls after disclosing government probe into asthma drug pricing at MarketWatch
09:31AM  Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions PR Newswire
08:09AM  Analyzing Pfizers Major Product Developments in 3Q15
01:00AM  Allergan CEO Saunders warms up to drug discovery
Nov-05-15 06:23PM  MERCK & CO., INC. Files SEC form 10-Q, Quarterly Report
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. It has a strategic collaboration with Bionomics Limited. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEEKS WENDELL PDirectorNov 04Option Exercise34.445,000172,2005,100Nov 04 04:37 PM
WEEKS WENDELL PDirectorNov 04Sale55.535,000277,669100Nov 04 04:37 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Option Exercise36.5637,3131,364,16357,008Oct 29 04:23 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Option Exercise35.0918,666654,990456,902Oct 30 04:58 PM
FRAZIER KENNETH CChairman, President & CEOOct 29Sale54.6918,6661,020,758438,236Oct 30 04:58 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerOct 29Sale55.0837,3132,055,33419,695Oct 29 04:23 PM
WENDELL PETER CDirectorOct 28Option Exercise34.445,000172,2006,000Oct 28 02:44 PM
WENDELL PETER CDirectorOct 28Sale54.855,000274,2371,000Oct 28 02:44 PM
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM